At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 50 enrolled
Drug / intervention
MMR vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Use of a Live Attenuated Vaccine Repurposed as an Innate Immune-based Preventive Against COVID-19-associated Sepsis/Inflammation
Louisiana State University Health Sciences Center in New Orleans·interventional·Posted Jul 17, 2020·Updated Nov 26, 2024
In Brief
A Phase 3 clinical trial evaluating MMR vaccine for Sepsis Syndrome. Completed, enrolled 50 participants across 1 site.
Detailed Summary
The objective of this randomized clinical trial is to test whether administration of live attenuated MMR vaccine (measles mumps rubella; Merck) to eligible adults at highest risk for contracting COVID-19 (healthcare workers, first responders), can induce non-specific trained innate immune leukocytes that can prevent/dampen pathological inflammation and sepsis associated with COVID-19-infection, if exposed.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSepsis Syndrome
CountriesUnited States
CollaboratorsParsemus Foundation
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartSep 2020
Primary CompletionMay 2022
TodayJul 2026
First PostedJul 17, 2020
Enrollment StartSep 22, 2020
Primary CompletionMay 15, 2022
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 6.0 years ago
Interventions
MMR vaccinebiological
Merck MMR-II vaccine